Stem cell therapy in dermatology

Sujay Khandpur, Savera Gupta, D R Gunaabalaji, Sujay Khandpur, Savera Gupta, D R Gunaabalaji

Abstract

Stem cells are precursor cells present in many tissues with ability to differentiate into various types of cells. This interesting property of plasticity can have therapeutic implications and there has been substantial research in this field in last few decades. As a result, stem cell therapy is now used as a therapeutic modality in many conditions, and has made its way in dermatology too. Stem cells can be classified on the basis of their source and differentiating capacity. In skin, they are present in the inter-follicular epidermis, hair follicle, dermis and adipose tissue, which help in maintaining normal skin homeostasis and repair and regeneration during injury. In view of their unique properties, they have been employed in treatment of several dermatoses including systemic sclerosis, systemic lupus erythematosus, scleromyxedema, alopecia, Merkel cell carcinoma, pemphigus vulgaris, psoriasis, wound healing, epidermolysis bullosa and even aesthetic medicine, with variable success. The advent of stem cell therapy has undoubtedly brought us closer to curative treatment of disorders previously considered untreatable. Nevertheless, there are multiple lacunae which need to be addressed including ideal patient selection, timing of intervention, appropriate conditioning regimens, post-intervention care and cost effectiveness. Further research in these aspects would help optimize the results of stem cell therapy.

Keywords: Dermatology; pemphigus; stem cell therapy; systemic lupus erythematosus; systemic sclerosis.

References

    1. The Nobel Prize in Physiology or Medicine. 2007; Available from: [Last retrieved on 2007 Oct 08]
    1. New Drugs and Clinical Trials Rules. The Gazette of India: Extraordinary [Part ii-Sec. 3(i)] G.S.R. 227(E). New Drugs and Clinical Trials Rules. 2019;
    1. Herzog EL, Chai L, Krause DS,. Plasticity of marrow-derived stem cells. Blood. 2003; 102:3483-93
    1. Schofield R,. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells. 1978; 4:7-25
    1. Monti M, Perotti C, Del Fante C, Cervio M, Redi CA, Fondazione IRCCS Policlinico San Matteo, Pavia (Italia). Stem cells: Sources and therapies. Biol Res. 2012; 45:207-14
    1. Prodinger CM, Reichelt J, Bauer JW, Laimer M,. Current and future perspectives of stem cell therapy in dermatology. Ann Dermatol. 2017; 29:667-87
    1. Ulloa-Montoya F, Verfaillie CM, Hu WS,. Culture systems for pluripotent stem cells. J Biosci Bioeng. 2005; 100:12-27
    1. Choi HR, Byun SY, Kwon SH, Park KC,. Niche interactions in epidermal stem cells. World J Stem Cells. 2015; 7:495-501
    1. Joulai Veijouye S, Yari A, Heidari F, Sajedi N, Ghoroghi Moghani F, Nobakht M,. Bulge region as a putative hair follicle stem cells niche: A brief review. Iran J Public Health. 2017; 46:1167-75
    1. Yamada T, Hasegawa S, Inoue Y, Date Y, Yamamoto N, Mizutani H, et al. Wnt/β-catenin and kit signaling sequentially regulate melanocyte stem cell differentiation in UVB-induced epidermal pigmentation. J Invest Dermatol. 2013; 133:2753-62
    1. Lan CC, Wu CS, Chiou MH, Hsieh PC, Yu HS,. Low-energy helium-neon laser induces locomotion of the immature melanoblasts and promotes melanogenesis of the more differentiated melanoblasts: Recapitulation of vitiligo repigmentation in vitro. J Invest Dermatol. 2006; 126:2119-26
    1. Awad SS,. Dermabrasion may repigment vitiligo through stimulation of melanocyte precursors and elimination of hyperkeratosis. J Cosmet Dermatol. 2012; 11:318-22
    1. Lan CC, Wu CS, Chen GS, Yu HS,. FK506 (tacrolimus) and endothelin combined treatment induces mobility of melanoblasts: New insights into follicular vitiligo repigmentation induced by topical tacrolimus on sun-exposed skin. Br J Dermatol. 2011; 164:490-6
    1. Fuchs E, Horsley V,. More than one way to skin. Genes Dev. 2008; 22:976-85
    1. Shahrokhi S, Menaa F, Alimoghaddam K, McGuckin C, Ebtekar M,. Insights and hopes in umbilical cord blood stem cell transplantations. J Biomed Biotechnol. 2012; 2012:572821
    1. Menaa F, Shahrokhi S, Shastri VP,. Corrigendum to “impact and challenges of mesenchymal stem cells in medicine: An overview of the current knowledge”. Stem Cells Int. 2019; 2019:5493654
    1. Mohammadi S, Malek Mohammadi A, Nikbakht M, Norooznezhad AH, Alimoghaddam K, Ghavamzadeh A,. Optimizing stem cells mobilization strategies to ameliorate patient outcomes: A review of guide-lines and recommendations. Int J Hematol Oncol Stem Cell Res. 2017; 11:78-88
    1. Gyurkocza B, Sandmaier BM,. Conditioning regimens for hematopoietic cell transplantation: One size does not fit all. Blood. 2014; 124:344-53
    1. Hatzimichael E, Tuthill M,. Hematopoietic stem cell transplantation. Stem Cells Cloning. 2010; 3:105-17
    1. Hsu YS, Cushing MM,. Autologous stem cell mobilization and collection. Hematol Oncol Clin N Am. 2016; 30:573-89
    1. Oyama Y, Parker ER, Brieva J, Guitart J, Statkute L, Verda L, et al. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory pemphigus foliaceus. Bone Marrow Transplant. 2004; 34:1097-8
    1. Suslova IM, Theodoropoulos DS, Cullen NA, Tetarnikova MK, Tetarnikov AS, Kolchak NA,. Pemphigus vulgaris treated with allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning. Eur Rev Med Pharmacol Sci. 2010; 14:785-8
    1. Vanikar AV, Trivedi HL, Patel RD, Kanodia KV, Modi PR, Shah VR,. Allogenic hematopoietic stem cell transplantation in pemphigus vulgaris: A single-center experience. Indian J Dermatol. 2012; 57:9-11
    1. Wang M, Cao C, Sun J, Peng X, Liu Q, Huang L, et al. Application of autologous hematopoietic stem cell transplantation for pemphigus. Int J Dermatol. 2017; 56:296-301
    1. Swart JF, Delemarre EM, van Wijk F, Boelens JJ, Kuball J, van Laar JM, et al. Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol. 2017; 13:244-56
    1. Oyama Y, Barr WG, Statkute L, Corbridge T, Gonda EA, Jovanovic B, et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant. 2007; 40:549-55
    1. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin JD, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: Long-term follow-up of the US multicenter pilot study. Blood. 2007; 110:1388-96
    1. Vonk MC, Marjanovic Z, van den Hoogen FH, Zohar S, Schattenberg AV, Fibbe WE, et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis. 2008; 67:98-104
    1. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: An observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2010; 95:284-92
    1. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): An open-label, randomised phase 2 trial. Lancet. 2011; 378:498-506
    1. Henes JC, Schmalzing M, Vogel W, Riemekasten G, Fend F, Kanz L, et al. Optimization of Autologous Stem Cell Transplantation for Systemic Sclerosis A single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol. 2012; 39:269-75
    1. Burt RK, Oliveira MC, Shah SJ, Moraes DA, Simoes B, Gheorghiade M, et al. Cardiac involvement and treatment-related mortality after nonmyeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: A retrospective analysis. Lancet. 2013; 381:1116-24
    1. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A randomized clinical trial. JAMA. 2014; 311:2490-8
    1. Henes JC, Koetter I, Horger M, Schmalzing M, Mueller K, Eick C, et al. Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. Rheumatology (Oxford). 2014; 53:919-22
    1. Del Papa N, Onida F, Zaccara E, Saporiti G, Maglione W, Tagliaferri E, et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant. 2017; 52:53-8
    1. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018; 378:35-47
    1. Nakamura H, Odani T, Yasuda S, Noguchi A, Fujieda Y, Kato M, et al. Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy. Mod Rheumatol. 2018; 28:879-84
    1. Nair V, Vasdev V, Kumar A, Shankar S, Nair V, Sharma A,. Stem cell transplant in systemic sclerosis: An Indian experience. Int J Rheum Dis. 2018; 21:859-65
    1. Walker UA, Saketkoo LA, Distler O,. Haematopoietic stem cell transplantation in systemic sclerosis. RMD Open. 2018; 4:e000533
    1. Pasquini MC, Voltarelli J, Atkins HL, Hamerschlak N, Zhong X, Ahn KW, et al. Transplantation for autoimmune diseases in North and South America: A report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2012; 18:1471-8
    1. British Society of Blood and Marrow Transplantation Indications table. Available from: [Last accessed on 2021 Feb 10]
    1. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2015; 21:1863-9
    1. Papa ND, Pignataro F, Zaccara E, Maglione W, Minniti A,. Autologous hematopoietic stem cell transplantation for treatment of systemic sclerosis. Front Immunol. 2018; 9:2390
    1. Burt RK, Oliveira MC, Shah SJ, Moraes DA, Simoes B, Gheorghiade M, et al. Cardiac involvement and treatment-related mortality after nonmyeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: A retrospective analysis. Lancet. 2013; 381:1116-24
    1. Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, et al. Haematopoietic SCT in severe autoimmune diseases: Updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012; 47:770-90
    1. Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I, et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: A retrospective study of the EBMT autoimmune disease working party. Blood. 2011; 118:1693-8
    1. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017; 76:1327-39
    1. Marmont AM, van Lint MT, Gualandi F, Bacigalupo A,. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus. 1997; 6:545-8
    1. Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood. 1998; 92:3505-14
    1. Fouillard L, Gorin NC, Laporte JP, Leon A, Brantus JF, Miossec P,. Control of severe systemic lupus erythematosus after high-dose immunusuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood. Lupus. 1999; 8:320-3
    1. Brunner M, Greinix HT, Redlich K, Knöbl P, Smolen J, Leitner G, et al. Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: A case report: Autologous Stem Cell Transplantation in Refractory SLE. Arthritis Rheum. 2002; 46:1580-4
    1. Lisukov IA, Sizikova SA, Kulagin AD, Kruchkova IV, Gilevich AV, Konenkova LP, et al. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus. Lupus. 2004; 13:89-94
    1. Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA. 2006; 295:527-35
    1. Gualandi F, Bruno B, Van Lint MT, Luchetti S, Uccelli A, Capello E, et al. Autologous stem cell transplantation for severe autoimmune diseases: A 10-year experience. Ann N Y Acad Sci. 2007; 1110:455-64
    1. Loh Y, Oyama Y, Statkute L, Traynor A, Satkus J, Quigley K, et al. Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus patients with cardiac dysfunction: Feasibility and reversibility of ventricular and valvular dysfunction with transplant-induced remission. Bone Marrow Transplant. 2007; 40:47-53
    1. Vanikar AV, Modi PR, Patel RD, Kanodia KV, Shah VR, Trivedi VB, et al. Hematopoietic stem cell transplantation in autoimmune diseases: The Ahmedabad experience. Transplant Proc. 2007; 39:703-8
    1. Alchi B, Jayne D, Labopin M, Demin A, Sergeevicheva V, Alexander T, et al. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: Data from the European Group for Blood and Marrow Transplantation registry. Lupus. 2013; 22:245-53
    1. Leng XM, Jiang Y, Zhou DB, Tian XP, Li TS, Wang SJ, et al. Good outcome of severe lupus patients with high-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation: A 10-year follow-up study. Clin Exp Rheumatol. 2017; 35:494-9
    1. Burt RK, Han X, Gozdziak P, Yaung K, Morgan A, Clendenan AM, et al. Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: Effect of conditioning regimen on outcome. Bone Marrow Transplant. 2018; 53:692-700
    1. Cao C, Wang M, Sun J, Peng X, Liu Q, Huang L, et al. Erratum corrige: “Autologous peripheral blood haematopoietic stem cell transplantation for systemic lupus erythematosus:the observation of long-term outcomes in a Chinese centre” C Cao et al. Clin Exp Rheumatol. 2018; 36:688
    1. Spierings J, van Laar JM,. Is there a place for hematopoietic stem cell transplantation in rheumatology?. Rheum Dis Clin North Am. 2019; 45:399-416
    1. Munir H, McGettrick HM,. Mesenchymal stem cell therapy for autoimmune disease: Risks and rewards. Stem Cells Dev. 2015; 24:2091-100
    1. Xu J,. Therapeutic applications of mesenchymal stem cells for systemic lupus erythematosus. Adv Exp Med Biol. 2018; 1089:73-85
    1. Owczarczyk-Saczonek A, Krajewska-Włodarczyk M, Kruszewska A, Placek W, Maksymowicz W, Wojtkiewicz J,. Stem cells as potential candidates for psoriasis cell-replacement therapy. Int J Mol Sci. 2017; 18:2182
    1. Chen W, Ren G, Zuo K, Huang X,. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report. Medicine (Baltimore). 2018; 97:e13589
    1. Kaffenberger BH, Wong HK, Jarjour W, Andritsos LA,. Remission of psoriasis after allogeneic, but not autologous, hematopoietic stem-cell transplantation. J Am Acad Dermatol. 2013; 68:489-92
    1. Gardembas-Pain M, Ifrah N, Foussard C, Boasson M, Saint Andre JP, Verret JL,. Psoriasis after allogeneic bone marrow transplantation. Arch Dermatol. 1990; 126:1523
    1. Snowden JA, Heaton DC,. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: Further evidence for adoptive autoimmunity. Br J Dermatol. 1997; 137:130-2
    1. Li X, Li J, Wang L, Niu X, Hou R, Liu R, et al. Transmission of psoriasis by allogeneic bone marrow transplantation and blood transfusion. Blood Cancer J. 2015; 5:e288
    1. Chen H, Niu JW, Ning HM, Pan X, Li XB, Li Y, et al. Treatment of psoriasis with mesenchymal stem cells. Am J Med. 2016; 129:e13-4
    1. Conget P, Rodriguez F, Kramer S, Allers C, Simon V, Palisson F, et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy. 2010; 12:429-31
    1. Hirsch T, Rothoeft T, Teig N, Bauer JW, Pellegrini G, De Rosa L, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature. 2017; 551:327-32
    1. El-Darouti M, Fawzy M, Amin I, Abdel Hay R, Hegazy R, Gabr H, et al. Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: A randomized controlled trial. Dermatol Ther. 2016; 29:96-100
    1. Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Woodley DT, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med. 2010; 363:629-39
    1. Petrof G, Lwin SM, Martinez-Queipo M, Abdul-Wahab A, Tso S, Mellerio JE, et al. Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2015; 135:2319-21
    1. Uitto J, Bruckner-Tuderman L, Christiano AM, McGrath JA, Has C, South AP, et al. Progress towards treatment and cure of epidermolysis bullosa: Summary of the DEBRA International Research Symposium EB2015. J Invest Dermatol. 2016; 136:352.e8
    1. Liang L, Bickenbach JR,. Somatic epidermal stem cells can produce multiple cell lineages during development. Stem Cells. 2002; 20:21-31
    1. Otero-Viñas M, Falanga V,. Mesenchymal stem cells in chronic wounds: The spectrum from basic to advanced therapy. Adv Wound Care (New Rochelle). 2016; 5:149-63
    1. Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng. 2007; 13:1299-312
    1. Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011; 92:26-36
    1. Legué E, Sequeira I, Nicolas JF,. Hair follicle renewal: Authentic morphogenesis that depends on a complex progression of stem cell lineages. Development. 2010; 137:569-77
    1. Mohanty S, Kumar A, Dhawan J, Sreenivas V, Gupta S,. Noncultured extracted hair follicle outer root sheath cell suspension for transplantation in vitiligo. Br J Dermatol. 2011; 164:1241-6
    1. Vinay K, Dogra S, Parsad D, Kanwar AJ, Kumar R, Minz RW, et al. Clinical and treatment characteristics determining therapeutic outcome in patients undergoing autologous non-cultured outer root sheath hair follicle cell suspension for treatment of stable vitiligo. J Eur Acad Dermatol Venereol. 2015; 29:31-7
    1. Fisch SC, Gimeno ML, Phan JD, Simerman AA, Dumesic DA, Perone MJ, et al. Pluripotent nontumorigenic multilineage differentiating stress enduring cells (Muse cells): A seven-year retrospective. Stem Cell Res Ther. 2017; 8:227
    1. Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S, et al. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol. 2005; 141:1277-82
    1. Illa I, de la Torre C, Rojas-Garcia R, Altes A, Blesa R, Sierra J, et al. Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: An in vivo and in vitro study. Blood. 2006; 108:773-4
    1. Anderi R, Makdissy N, Azar A, Rizk F, Hamade A,. Cellular therapy with human autologous adipose-derived adult cells of stromal vascular fraction for alopecia areata. Stem Cell Res Ther. 2018; 9:141
    1. Shin H, Ryu HH, Kwon O, Park BS, Jo SJ,. Clinical use of conditioned media of adipose tissue-derived stem cells in female pattern hair loss: A retrospective case series study. Int J Dermatol. 2015; 54:730-5
    1. Gentile P, Scioli MG, Bielli A, Orlandi A, Cervelli V,. Stem cells from human hair follicles: First mechanical isolation for immediate autologous clinical use in androgenetic alopecia and hair loss. Stem Cell Investig. 2017; 4:58
    1. Elmaadawi IH, Mohamed BM, Ibrahim ZA, Abdou SM, El Attar YA, Youssef A, et al. Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia. J Dermatolog Treat. 2018; 29:431-40
    1. Li Y, Yan B, Wang H, Li H, Li Q, Zhao D, et al. Hair regrowth in alopecia areata patients following Stem Cell Educator therapy. BMC Med. 2015; 13:87
    1. Stevens HP, Donners S, de Bruijn J,. Introducing Platelet-Rich Stroma: Platelet-Rich Plasma (PRP) and Stromal Vascular Fraction (SVF) Combined for the Treatment of Androgenetic Alopecia. Aesthet Surg J. 2018; 38:811-22
    1. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360:692-8
    1. Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature. 2019; 568:244-8
    1. Menaa F,. Viral etiology of merkel cell carcinoma: Implications in diagnosis, prognosis, therapy and prevention. Int J Clin Dermatol Res. 2015; 3:1-2
    1. Sunshine JC, Jahchan NS, Sage J, Choi J,. Are there multiple cells of origin of Merkel cell carcinoma?. Oncogene. 2018; 37:1409-16
    1. Waldmann V, Goldschmidt H, Jäckel A, Deichmann M, Hegenbart U, Hartschuh W, et al. Transient complete remission of metastasized Merkel cell carcinoma by high-dose polychemotherapy and autologous peripheral blood stem cell transplantation. Br J Dermatol. 2000; 143:837-9
    1. Menaa F, Houben R, Eyrich M, Broecker EB, Becker JC, Wischhusen J,. Stem cells, melanoma and cancer stem cells: The good, the bad and the evil?. G Ital Dermatol Venereol. 2009; 144:287-96
    1. Chow P, Moore S, Kaushik G,. Melanoma stem cells: The past, present and future. J Stem Cell Res Ther. 2018; 4:89-90
    1. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature. 2008; 451:345-9
    1. Menaa F,. Latest approved therapies for metastatic melanoma: What comes next?. J Skin Cancer. 2013; 2013:735282
    1. Houben R, Wischhusen J, Menaa F, Synwoldt P, Schrama D, Bröcker EB, et al. Melanoma stem cells: Targets for successful therapy?. J Dtsch Dermatol Ges. 2008; 6:541-6
    1. Kim JH, Jung M, Kim HS, Kim YM, Choi EH,. Adipose-derived stem cells as a new therapeutic modality for ageing skin. Exp Dermatol. 2011; 20:383-7
    1. Kim WS, Park BS, Park SH, Kim HK, Sung JH,. Antiwrinkle effect of adipose-derived stem cell: Activation of dermal fibroblast by secretory factors. J Dermatol Sci. 2009; 53:96-102
    1. Mehrabani D, Manafi N,. Role of cultured skin fibroblasts in aesthetic and plastic surgery. World J Plast Surg. 2013; 2:2-5
    1. Indian Council of Medical Research. National Guidelines for Stem Cell Research. 2017; Available from: [Last accessed on 2019 Dec 26]
    1. Sabha L,. Government of India Ministry of Health and Family Welfare, Lok Sabha, Unstarred Question No. 3448. Published Online 2017
    1. Tiwari SS, Desai PN,. Unproven stem cell therapies in India: Regulatory challenges and proposed paths forward. Cell Stem Cell. 2018; 23:649-52

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться